Becton, Dickinson and Company (NYSE:BDX) Releases FY24 Earnings Guidance

Becton, Dickinson and Company (NYSE:BDX) issued an update on its FY24 earnings guidance on Thursday morning. The company provided earnings per share guidance of $12.95-13.15 for the period, compared to the consensus earnings per share estimate of $12.95. The company issued revenue guidance of ~$20.1-20.3 billion, compared to the consensus revenue estimate of $20.30 billion.

Becton, Dickinson and Company Stock Performance

BDX traded down $5.67 during trading hours on Friday, reaching $234.68. The company’s stock had a trading volume of 1,722,353 shares, compared to its average volume of 1,291,373. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.64 and a current ratio of 1.41. The company’s 50-day moving average is $238.45 and its 200-day moving average is $240.53. Becton, Dickinson and Company has a 52 week low of $229.40 and a 52 week high of $287.32. The firm has a market cap of $67.80 billion, a PE ratio of 51.69, a price-to-earnings-growth ratio of 1.93 and a beta of 0.45.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.97 by $0.20. The business had revenue of $5.05 billion during the quarter, compared to the consensus estimate of $5.04 billion. Becton, Dickinson and Company had a return on equity of 13.90% and a net margin of 6.76%. The firm’s quarterly revenue was up 4.6% on a year-over-year basis. During the same period in the previous year, the company posted $2.86 EPS. On average, equities analysts forecast that Becton, Dickinson and Company will post 13.04 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 28th. Investors of record on Monday, June 10th will be paid a $0.95 dividend. This represents a $3.80 annualized dividend and a dividend yield of 1.62%. The ex-dividend date of this dividend is Monday, June 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 83.70%.

Analyst Ratings Changes

Separately, Barclays lifted their price objective on Becton, Dickinson and Company from $301.00 to $305.00 and gave the company an overweight rating in a report on Monday, February 5th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of Moderate Buy and a consensus target price of $280.00.

Insider Buying and Selling

In other news, SVP Thomas J. Spoerel sold 282 shares of Becton, Dickinson and Company stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $238.29, for a total value of $67,197.78. Following the transaction, the senior vice president now owns 2,276 shares in the company, valued at approximately $542,348.04. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In related news, SVP Thomas J. Spoerel sold 282 shares of the stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $238.29, for a total value of $67,197.78. Following the completion of the transaction, the senior vice president now owns 2,276 shares of the company’s stock, valued at approximately $542,348.04. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Michael David Garrison sold 1,715 shares of the business’s stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total value of $399,269.15. Following the sale, the executive vice president now owns 5,381 shares in the company, valued at approximately $1,252,750.61. The disclosure for this sale can be found here. 0.31% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.